Global Journal of Life Sciences and Biological Research
Open Access
ISSN: 2456-3102
ISSN: 2456-3102
Debra Kimless, MD*, J. Phillip Kennedy, PhD, Janet Zand
Background: Microplastics and nanoplastics have emerged as pervasive environmental contaminants now detectable in human tissues, with potential links to oxidative stress, endocrine disruption and chronic inflammation. No established interventions currently exist to reduce internal plastic burden. The Plastic Adsorptive Compound (PAC) was developed as a food-grade oral supplement designed to adsorb ingested micro and nanoplastics within the gastrointestinal tract and facilitate their elimination before systemic absorption. Methods: An open-label, proof-of-concept study pilot study (IRB-approved) enrolled seven adult participants who took PAC capsules two capsules three times daily with meals for 30 days. Each capsule contained food-grade ingredients designated as Generally Recognized as Safe (GRAS). Blood and saliva microplastic levels were assayed pre- and post-intervention using a standardized spectroscopic polymer identification assay. Results: All participants completed the 30-day protocol without adverse events. Analysis demonstrated a mean 74% reduction in detectable plastic particle concentration in post-treatment blood samples compared with baseline values. Participants reported no significant gastrointestinal symptoms or other side effects, indicating good tolerability of PAC. Conclusion: This preliminary study suggests that PAC may substantially reduce systemic micro- and nanoplastic burden through enteric adsorption and prevention of plastic absorption. These promising results warrant confirmation in larger, randomized, placebo-controlled trials to validate efficacy, define optimal dosing, and elucidate long-term safety and mechanisms of action.
Published Date: 2025-12-04; Received Date: 2025-11-04